SEC Form 4 · accession 0000899243-17-027190

scPharmaceuticals Inc. · SCPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 21, 2017

Accepted (ET)

Nov 21, 2017 · 7:17 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001604950

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Nov 21, 2017	C	2,576,532	—	A	2,576,532	I	By: OrbiMed Private Investments VI, L.P.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Preferred Stock^F2,F3	—	Nov 21, 2017	C	18,500,000	D	—	—	Common Stock	2,576,532	0	I

F1Represents the total number of shares of Common Stock received by OrbiMed Private Investments VI, L.P. ("OPI VI"), upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
F2The shares of Series B Preferred Stock are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP VI. Jonathan Silverstein, a natural person, is a managing member of, and holder of a controlling interest in Advisors. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose.
F3All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date.